ArticleImplementation science communications2026
What constitutes risk in implementation research? Perspectives from a qualitative key-informant study.
Article in Implementation science communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs implementation research increasingly occurs within routine care settings, determining what constitutes minimal risk is critical to ensuring that ethical oversight is appropriate and proportional. Current regulatory definitions often do not reflect the unique features of implementation studies, including implementation strategy-related risks and system-level effects. Yet, little empirical evidence exists on how researchers themselves interpret minimal risk in this context.
methodsWe conducted semi-structured qualitative interviews with 11 key informants, including investigators with experience in domestic and global implementation research. Participants were recruited through purposive sampling. Interviews explored how participants interpret the concept of minimal risk, identify risk-related concerns, and experience regulatory review processes as they relate to risk assessment. Data were analyzed thematically using a grounded theory approach.
resultsParticipants generally accepted the U.S. Federal Policy for the Protection of Human Subjects (Common Rule) definition of minimal risk but viewed its application to implementation research as complex and context-dependent. Four major themes emerged: (1) ambiguity in defining usual care, especially in low-resource or inequitable settings; (2) distinguishing between strategy-related and intervention-related risks, (3) clarifying who or what is at risk, and (4) understanding the types of risks most likely to arise in implementation research contexts. Participants expressed concern that strategy-related risks, such as staff burden or organizational disruption, are poorly conceptualized, underreported, and inconsistently reviewed by ethics review committees. At the same time, they raised unresolved questions about who should bear responsibility for monitoring risks tied to the evidence-based intervention itself.
conclusionsGreater clarity is needed to guide ethical review, particularly regarding implementation strategy-related risks and the responsibilities of researchers for intervention-related harms. We recommend that implementation researchers begin systematically documenting and publishing on unintended harms related to implementation strategies, and that the field invest in building ethical frameworks and training specific to these challenges. Without such efforts, implementation science risks undermining the very systems and communities it seeks to improve.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.